Orca Security Offers Best-in-Class Approach to Secure Cloud-Native Applications, Expanding with ThreatOptix’s Agent-Based Runtime Protection
21.2.2023 14:00:00 EET | Business Wire | Press release
Orca Security, the pioneer of agentless cloud security, today announced that the Orca Cloud Security Platform will include ThreatOptix’s agent-based runtime protection and enforcement for cloud-native applications, including virtual machines, containers, and Kubernetes applications. While Orca remains committed to agentless cloud security, this new capability builds on Orca's industry leadership in delivering the most comprehensive coverage and visibility across the cloud estate and offers customers a choice in how they want to secure their applications.
New capabilities from ThreatOptix, whose technology provides comprehensive Linux security with an emphasis on cloud workload protection, will enhance the runtime detection and enforcement within the Orca Cloud Security Platform. The new features in the Orca Platform will be delivered via a strategic partnership with ThreatOptix, where all agent deployments and policy management, as well as data, will be fully integrated into the Orca Platform and sold as a single platform.
Security teams have many challenges in securing modern workloads, including vulnerability management, compliance monitoring, and advanced threat detection and prevention. Orca has been solely focused on delivering best-in-breed agentless capabilities to address these concerns. Yet there are specific mission critical applications where organizations may require an agent for advanced runtime protection and enforcement.
According to Enterprise Strategy Group*, “The growing footprint of Linux-based workloads, both virtual machine instances and application containers, has become a more prominent facet of the attack surface. Because these assets are temporal, they are often not running when security analysts are conducting investigations. As such, capturing system activity with an EDR offering that is purpose-built for Linux workloads is required.”
“At Orca Security, we have a mission to continually innovate cloud security and push the limits of what’s possible to be your key partner for securing the entirety of your cloud environments now and in the future,” said Avi Shua, CEO and co-founder of Orca Security. “As we expand our Cloud Security Platform, we are strategically partnering with ThreatOptix due to their core focus on delivering runtime protection and enforcement for cloud-native applications.”
ThreatOptix was founded by Ehud (“Udi”) Shamir and Sameet Mehta. Udi co-founded the XDR pioneer SentinelOne, where Sameet served as CFO, and both bring years of experience in workload runtime protection.
“At ThreatOptix, we have focused on cloud workload protection from inception,” said Udi Shamir. “The existing EDR solutions are not optimized to address the dynamic and ephemeral nature of modern cloud-native applications that run on containers and Kubernetes. Partnering with Orca, the leader in agentless cloud security, will strengthen an already innovative solution to better address the use cases for deploying an agent for cloud workload protection.”
Upon this integration, Orca Cloud Security Platform customers will be able to immediately deploy and manage the ThreatOptix agent as well as configure policies from the Orca UI. All agent-based runtime telemetry will be fully available within the Orca Unified Data Model to ensure ease-of-use and operation.
“Many partnerships in the cybersecurity ecosystem lack a deep integration strategy. This leads to duct-taped solutions that are inefficient and lack value for their users,” said Gil Geron CPO and co-founder of Orca Security. “We believe this strategic partnership and integration will be transformative for securing the cloud in a purpose-built way to deliver a seamless solution sold under a single SKU. Once integrated, Orca customers will have a seamless experience with the agent acting similarly to a native Orca capability. The Platform will support all cloud environments secured by us today, including highly regulated environments like FedRAMP.”
To learn more about how Orca is focused on securing cloud environments and addressing cloud risks, visit the Orca Blog. Additionally, organizations interested in trialing the Orca Platform can sign up for a free, 30-day cloud risk assessment.
Availability
The integrated solution will be available in the second half of 2023.
About Orca Security
Orca Security is the pioneer of agentless cloud security that is trusted by hundreds of enterprises globally. Orca makes cloud security possible for enterprises moving to and scaling in the cloud with its patented SideScanning™ technology and Unified Data Model. The Orca Cloud Security Platform delivers the world's most comprehensive coverage and visibility of all risks across the cloud. With this continuous first-to-market innovations and expertise, the Orca Cloud Security Platform ensures security teams quickly identify and remediate risks to keep their businesses secure. Connect your first account in minutes: https://orca.security or take the free cloud risk assessment.
About ThreatOptix
ThreatOptix provides peerless server protection architected from the ground-up to defend Linux, with a technology that makes it easy for large enterprises and government agencies to detect, classify and mitigate threats with greater efficacy than any existing offering.
* ESG: The Maturation of Cloud-native Security 2021
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005278/en/
Contact information
Media
Emily Townsend
fama PR for Orca Security
orca@famapr.com
Kirtee Londhe Mehta
PR for ThreatOptix, Inc.
kirtee@threatoptix.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
